Roche presented results from several Phase II and III trials at the 7th Congress of the European Academy of Neurology (EAN) Annual Meeting held virtually June 19-22.
GlaxoSmithKline and Vir Biotechnology said final results from a late-stage study of their monoclonal antibody confirmed sotrovimab significantly reduced hospitalization and death among high-risk Covid-19 patients when given early in the disease.
Eli Lilly and Company announced the launch of a head-to-head study to compare once-monthly injectable Emgality (galcanezumab-gnlm) with Nurtec ODT (rimegepant) for the prevention of migraine.
AstraZeneca said a late-stage trial failed to provide evidence that the company’s Covid-19 antibody therapy protected people who had contact with an infected person from the disease, a small setback in its efforts to find alternatives to vaccines.
Britain’s GlaxoSmithKline Plc agreed to pay up to $2 billion to iTeos Therapeutics Inc. to develop and sell a potential cancer treatment together, the companies said on June 14.
The U.S. health regulator authorized a lower dose of Regeneron Pharmaceuticals’ Covid-19 antibody cocktail that can be given by injection, a move that could ease logistical challenges stemming from administering a higher dose intravenously.
The U.S. Food and Drug Administration gave an emergency use authorization to the antibody treatment developed by Vir Biotechnology and GlaxoSmithKline for treating mild-to-moderate Covid-19 in people aged 12 years and older.
Antiviral pills against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel coronavirus responsible for coronavirus disease 2019 (Covid-19), are showing promise in new clinical trials.
Pivotal data from Amgen’s and AstraZeneca’s NAVIGATOR Phase III trial show tezepelumab, a potential first-in-class human monoclonal antibody, reduced asthma aggravations and exacerbations requiring hospitalizations better than placebo in patients with severe asthma.
In a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, researchers found when a new monoclonal antibody drug was added to treatments being given to hospitalized Covid-19 patients who were still breathing on their own, Humanigen Inc.’s lenzilumab significantly improved their odds of not needing invasive mechanical ventilation.